Crisis-driven Growth Opportunities on Hemophilia Treatment Drugs Market

Hemophilia Treatment Drugs Market – Snapshot

The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.

Request Sample Of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900

The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.

Request the Coronavirus Impact Analysis on this Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1900

The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.

Buy Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=1900&ltype=S

In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.

Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.